Confocal laser endomicroscopy detects colonic inflammation in patients with irritable bowel syndrome: a prospective study

Abstract

Background and aims Irritable bowel syndrome (IBS) is considered to be a functional disease, but recent data indicate measurable organic alterations. We aimed to determine the presence of colorectal mucosa microinflammation in vivo via probe-confocal laser endomicroscopy (pCLE) and histological evaluation in IBS patients.

Methods This was a prospective, controlled, nonrandomized single-blind diagnostic trial performed in a tertiary institution. pCLE images and targeted biopsy of each colon segment obtained during colonoscopies of IBS patients and controls were analyzed for inflammatory changes. Biopsies were classified using the Geboes scale, and the odds ratio and overall diagnostic accuracy were calculated.

Results During the 15-month study period, 37 patients were allocated to each group. The mean age was 53.1 ± 14.3 years; 64.9 % were female. Signs of colonic mucosa inflammation were evident on 65.8 % of pCLE images from IBS patients compared to 23.4 % of images from controls (OR 6.28; 4.14–9.52; P < 0.001). In total, 20/37 patients had microinflammation via pCLE in ≥ 3 colon segments in the IBS group, compared to 1/37 in the control group. A Geboes score > 0 was attributed to 60.8 % of biopsies from patients in the IBS group compared to 27.5 % of biopsies from the control group. The sensitivity, specificity, positive and negative predictive values, observed and interrater agreement of pCLE-detected inflammatory changes in IBS using histology as gold standard were 76 %, 91 %, 76 %, 91 %, 86.5 %, and 66.8 %, respectively.

Conclusions Patients with IBS have a six-fold higher prevalence of colorectal mucosa microinflammation than healthy controls. pCLE might be a reliable method to detect colorectal mucosa microinflammation in IBS patients.

Publication History

Received: 19 July 2019

Accepted: 20 December 2019

Article published online:
23 March 2020

• References

• 1 Longstreth GF, Thompson WG, Chey WD. et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
• 2 Lacy BE, Mearin F, Chang L. et al. Bowel disorders. Gastroenterology 2016; 150: 1393-1407
• 3 Palsson OS, Whitehead WE, van Tilburg MAL. et al. Development and validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology 2016; 150: 1481-1491
• 4 Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390
• 5 Choghakhori R, Abbasnezhad A, Hasanvand A. et al. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life. Cytokine 2017; 93: 34-43
• 6 Seyedmirzaee S, Hayatbakhsh MM, Ahmadi B. et al. Serum immune biomarkers in irritable bowel syndrome. Clin Res Hepatol Gastroenterol 2016; 40: 631-637
• 7 Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 6759
• 8 Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988
• 9 Shulman RJ, Jarrett ME, Cain KC. et al. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 2014; 49: 1467-1476
• 10 Boyer J, Saint-Paul M-C, Dadone B. et al. Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study. Neurogastroenterol Motil 2018; 30: e13223
• 11 Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011; 46: 421-431
• 12 Bashashati M, Moossavi S, Cremon C. et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2018; 30: e13192
• 13 Ohman L, Isaksson S, Lundgren A. et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-986
• 14 Barbara G, De Giorgio R, Stanghellini V. et al. A role for inflammation in irritable bowel syndrome?. Gut 2002; 51 (Suppl. 01) 41-44
• 15 Chey WD, Nojkov B, Rubenstein JH. et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol 2010; 105: 859-865
• 16 Robles-Medranda C, Vargas M, Ospina J. et al. Clinical impact of confocal laser endomicroscopy in the management of gastrointestinal lesions with an uncertain diagnosis. World J Gastrointest Endosc 2017; 16: 389-395
• 17 Turcotte J-F, Kao D, Mah SJ. et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). Gastrointest Endosc 2013; 77: 624-630
• 18 Li C-Q, Xie X-J, Yu T. et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. Am J Gastroenterol 2010; 105: 1391-1396
• 19 Fritscher-Ravens A, Schuppan D, Ellrichmann M. et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology 2014; 147: 1012-1020
• 20 Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-924
• 21 Geboes K, Riddell R, Ost A. et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000; 47: 404-409
• 22 Günther U, Kusch D, Heller F. et al. Surveillance colonoscopy in patients with inflammatory bowel disease: comparison of random biopsy vs. targeted biopsy protocols. Int J Colorectal Dis 2011; 26: 667-672
• 23 Robles-Medranda C, Valero V, Puga-Tejada M. et al. Mo1992 cost-effective analysis comparing standard biopsy vs. digital biopsy by confocal endomicroscopy. Gastrointest Endosc 2017; 85 (05) AB510-AB511
• 24 Barbara G, Cremon C, Annese V. et al. Randomised controlled trial of mesalazine in IBS. Gut 2016; 65: 82-90